Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

mRNA vaccine - GlaxoSmithKline

Next Previous
Drug Profile

mRNA vaccine - GlaxoSmithKline

Alternative Names: Flu mRNA vaccine; GSK6479715A; GSK6479720A

Latest Information Update: 12 Jun 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GSK
  • Class Influenza virus vaccines; RNA vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Influenza virus infections

Most Recent Events

  • 11 May 2026 GlaxoSmithKline completes a phase IIa trial in Influenza virus infections (In volunteers) in USA and Belgium (IM, Injection) (NCT07121192) (CTIS2025-522278-35-00)
  • 25 Aug 2025 Preclinical trials in Influenza virus infections in United Kingdom (IM), prior to August 2025

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top